Sort
82,697 grants matching “vaccine development”
The Institute for Biomolecular Targeting
$2,460,000Dean R Madden · Dartmouth College · P20 · FY2024 · GM
CANCER CENTER SUPPORT GRANT
$2,459,346Gerold Bepler · Wayne State University · P30 · FY2014 · CA
DENVER AUTOIMMUNITY CENTER OF EXCELLENCE
$2,459,269University Of Colorado Denver · U19 · FY2002 · AI
Core C: Biosecurity Core
$2,458,772James W. Leduc · University Of Texas Med Br Galveston · UC7 · FY2022 · AI
Optimizing Human B and T Cell Vaccines Against HIV Using Humanized BLT Mice
$2,458,248Todd M Allen · Massachusetts General Hospital · P01 · FY2016 · AI
COVID-19 Clinical Support and Research
$2,457,478Adrian McDermott · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
A NOVEL VEE REPLICON VACCINE FOR HIV
$2,456,857University Of North Carolina Chapel Hill · P01 · FY2001 · AI
AIDS associated Toxoplasma encephalitis
$2,456,732Louis M. Weiss · Albert Einstein College Of Medicine · R01 · FY2025 · AI
Development of a recombinant trimeric RSV-F vaccine (DS-Cav1)
$2,456,526Frank Arnold · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Disease Emergence and Elimination: Using Mobility Data to Inform Spatial Disease Dynamics
$2,456,250Amy Wesolowski · Johns Hopkins University · DP2 · FY2018 · LM
University of Pittsburgh Clinical Trials Unit
$2,455,069John W Mellors · University Of Pittsburgh At Pittsburgh · U01 · FY2011 · AI
Optimizing Human B and T Cell Vaccines Against HIV Using Humanized BLT Mice
$2,454,595Todd M Allen · Massachusetts General Hospital · P01 · FY2017 · AI
The Influence of Aerodynamic Particle Size on the Virulence of Aerosolized Ebola Virus
$2,454,590National Institute Of Allergy And Infectious Diseases · Y01 · FY2018 · AI
Development of a Next Generation Anthrax Vaccine, dmPA7909
$2,454,564Sukjoon Park · Emergent Product Development Gaithersbur · U01 · FY2009 · AI
Arming the Immune System Against Pathogens
$2,453,989Harvard University (Sch Of Public Hlth) · P01 · FY2003 · AI
SPORE in Soft Tissue Sarcoma
$2,453,831Samuel Singer · Sloan-Kettering Inst Can Research · P50 · FY2025 · CA
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
$2,453,778Jamey P Weichert · University Of Wisconsin-Madison · P01 · FY2022 · CA
Development of Novel Vaccine Strategies
$2,453,605Jeffrey Schlom · Basic Sciences · Z01 · FY2007 · CA
ADVANCING VACCINE ADJUVANT RESEARCH FOR TUBERCULOSIS (AVAR-T)
$2,453,560Warwick Britton · University Of Sydney · N01 · FY2022 · AI
Transforming Human Pancreatic Cancer Into An Immunologic Disease
$2,453,222Elizabeth Marion Jaffee · Johns Hopkins University · P01 · FY2024 · CA
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
$2,452,679Jamey P Weichert · University Of Wisconsin-Madison · P01 · FY2023 · CA
Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses
$2,452,497Pascal Poignard · International Aids Vaccine Initiative · U19 · FY2012 · AI
Optical Technologies and Molecular Imaging for Cervical Neoplasia
$2,451,402Michele Follen · Drexel University · P01 · FY2010 · CA
Spore in Head and Neck Cancer
$2,451,382David Sidransky · Johns Hopkins University · P50 · FY2015 · DE
NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF MHRP GP145 CLADE C PROTEIN
$2,450,937Nancy Lin · Advanced Bioscience Laboratories, Inc. · N01 · FY2014 · AI